stockrow
Friday 6 November 2026
Export BBIO’s income statement to Excel — free account
BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +67.5%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
74.28
0.01
+0.01%
Follow BBIO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
29.18 | 24.94 | 20.45 | 13.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(259.66) | (73.32) | (205.09) | (292.03) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
31.71 | 26.65 | 22.15 | 14.06 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(35.70) | (34.81) | (36.36) | (36.03) | |
EV/FCF |
(34.94) | (34.07) | (35.58) | (35.14) | |
Quick Ratio |
2.52 | 1.40 | 1.09 | 1.96 | |
Current Ratio |
2.77 | 1.52 | 1.23 | 2.09 | |
Net Debt/EBITDA |
(9.26) | (9.58) | (11.60) | (45.13) | |
Debt/Assets |
197.91% | 140.49% | 158.35% | 89.23% | |
Debt/Equity |
(0.89) | (0.85) | (0.77) | (1.17) | |
Asset Turnover |
0.54 | 0.51 | 0.62 | 0.60 | |
Operating CF/Net income |
0.29 | 1.20 | 0.47 | 0.53 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.15) | (0.10) | |
Interest Coverage |
(2.77) | (2.01) | (1.96) | (0.21) | |
Research and Development Expense of Revenue |
75.51% | 65.10% | 61.33% | 40.63% | |
Selling, General and Administrative Expense of Revenue |
102.53% | 84.26% | 76.44% | 56.87% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.02 | 0.01 | |
Share Based Compensation of Revenue |
22.47% | 17.09% | 18.09% | 11.29% | |
Graham Net Nets |
(0.15) | (0.17) | (0.18) | (0.14) | |
Graham Number |
30.36 | 31.30 | 32.06 | 29.53 | |
Earnings Yield |
(4.94%) | (5.04%) | (4.79%) | (4.45%) | |
Free Cash Flow Yield |
(3.11%) | (3.14%) | (3.04%) | (2.93%) | |
Revenue per Share |
0.81 | 1.00 | 1.24 | 1.80 | |
Operating CF per Share |
(0.29) | (1.01) | (0.36) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.29) | (1.01) | (0.37) | (0.23) | |
Cash per Share |
3.07 | 4.83 | 3.68 | 7.85 | |
Shareholders Equity per Share |
(10.84) | (11.64) | (12.79) | (8.43) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.84) | (11.64) | (12.79) | (8.43) | |
Free Cash Flow |
(56.45) | (197.35) | (71.54) | (44.46) | |
Working Capital |
509.78 | 424.93 | 202.49 | 1,067.37 | |
Capital Expenditures |
(0.03) | (0.07) | (0.44) | (0.29) | |
Net Current Asset Value |
(2,214.29) | (2,397.60) | (2,629.04) | (1,769.32) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
72.08 | 160.25 | 165.68 | 245.80 | |
Average Payables |
22.92 | 28.29 | 26.67 | 53.48 | |
Average Inventory |
— | 18.47 | 35.56 | 42.12 | |
Average Assets |
927.68 | 1,126.31 | 1,148.74 | 1,580.02 | |
Average Common Equity |
(1,766.88) | (1,953.18) | (2,141.42) | (2,258.69) |
Columns are period end dates · fundamentals updated 6 Nov 2026